Ocugen to Showcase Gene Therapy Platform at Key July Conferences — Ocugen, Inc.

Event summary

Ocugen will present at three industry conferences in July 2026, including Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and ASRS.
CEO Shankar Musunuri to participate in a fireside chat on July 10, 2026.
Phase 2 ArMaDa 1-Year results for OCU410 to be presented at ASRS on July 17, 2026.
Webcast of Piper Sandler presentation available on Ocugen’s investor relations page.

The big picture

Ocugen’s participation in these conferences underscores its focus on advancing gene therapies for blindness diseases. The presentations come at a critical time as the company seeks to validate its modifier gene therapy platform, which aims to address complex diseases through a gene-agnostic approach. Success in these forums could bolster Ocugen’s standing among investors and regulators, particularly as it navigates the competitive landscape of retinal disease treatments.

What we're watching

Clinical Data Impact: How the Phase 2 ArMaDa results for OCU410 will influence investor sentiment and regulatory path forward.
Market Positioning: Whether Ocugen can differentiate its modifier gene therapy platform in a competitive ophthalmology space.
Execution Risk: The pace at which Ocugen advances its pipeline given the complexity of addressing multiple gene networks.